A study in sporadic breast cancer by Margeli's group [108] found that patients with lower BRCA1 mRNA expression who were treated with neoadjuvant chemotherapy (fluorouracil, epirubicin, and cyclophosphamide) had a lower relapse rate and longer survival when compared to patients with higher BRCA1 expression. Here, BRCA1 is linked to breast cancer.